2020–2021 Drug Updates in Hematologic Malignancies

During JADPRO Live Virtual 2021, Kirollos Hanna, PharmD, BCPS, BCOP, discussed the label indications of drugs and biologics in hematologic malignancies approved from late 2020 to late 2021, including mechanisms of action and various safety profiles so advanced practitioners can manage and treat pati...

Descripción completa

Detalles Bibliográficos
Autor principal: Hanna, Kirollos
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Harborside Press LLC 2022
Materias:
Meeting Reports
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9126337/
https://www.ncbi.nlm.nih.gov/pubmed/35663174
http://dx.doi.org/10.6004/Jadpro.2022.13.3.20
_version_ 1784712104784166912
author Hanna, Kirollos
author_facet Hanna, Kirollos
author_sort Hanna, Kirollos
collection PubMed
description During JADPRO Live Virtual 2021, Kirollos Hanna, PharmD, BCPS, BCOP, discussed the label indications of drugs and biologics in hematologic malignancies approved from late 2020 to late 2021, including mechanisms of action and various safety profiles so advanced practitioners can manage and treat patients safely with these new and approved therapeutic agents. In particular, CAR T-cell therapies were approved across many hematologic malignancies, along with PI3K inhibitors, anti-CD38 monoclonal antibodies, and immunotherapies.
format Online
Article
Text
id pubmed-9126337
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Harborside Press LLC
record_format MEDLINE/PubMed
spelling pubmed-91263372022-06-04 2020–2021 Drug Updates in Hematologic Malignancies Hanna, Kirollos J Adv Pract Oncol Meeting Reports During JADPRO Live Virtual 2021, Kirollos Hanna, PharmD, BCPS, BCOP, discussed the label indications of drugs and biologics in hematologic malignancies approved from late 2020 to late 2021, including mechanisms of action and various safety profiles so advanced practitioners can manage and treat patients safely with these new and approved therapeutic agents. In particular, CAR T-cell therapies were approved across many hematologic malignancies, along with PI3K inhibitors, anti-CD38 monoclonal antibodies, and immunotherapies. Harborside Press LLC 2022-04 2022-05-23 /pmc/articles/PMC9126337/ /pubmed/35663174 http://dx.doi.org/10.6004/Jadpro.2022.13.3.20 Text en © 2022 Harborside™ https://creativecommons.org/licenses/by-nc-nd/3.0/This article is distributed under the terms of the Creative Commons Attribution Non-Commercial Non-Derivative License, which permits unrestricted non-commercial and non-derivative use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Meeting Reports
Hanna, Kirollos
2020–2021 Drug Updates in Hematologic Malignancies
title 2020–2021 Drug Updates in Hematologic Malignancies
title_full 2020–2021 Drug Updates in Hematologic Malignancies
title_fullStr 2020–2021 Drug Updates in Hematologic Malignancies
title_full_unstemmed 2020–2021 Drug Updates in Hematologic Malignancies
title_short 2020–2021 Drug Updates in Hematologic Malignancies
title_sort 2020–2021 drug updates in hematologic malignancies
topic Meeting Reports
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9126337/
https://www.ncbi.nlm.nih.gov/pubmed/35663174
http://dx.doi.org/10.6004/Jadpro.2022.13.3.20
work_keys_str_mv AT hannakirollos 20202021drugupdatesinhematologicmalignancies

Ejemplares similares